# Genomics Medicine Ireland

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genomics-medicine-ireland

- Industry: Biotechnology
- Headquarters: Dublin, Ireland
- Website: www.genomicsmedicineireland.ie
- Total disclosed funding: $40M
- Latest round: Series A (Oct 26, 2016)
- Investors on record: 4

## About

Genomics Medicine Ireland Limited specializes in genomic solutions that enhance healthcare by analyzing genetic influences on diseases, providing advanced sequencing and bioinformatics services to improve patient outcomes through personalized medicine.Founded in 2015, Genomics Medicine Ireland Limited is based in Dublin, Ireland. The company focuses on genomic solutions aimed at advancing healthcare through genetic insights. In November 2018, Genuity Science acquired Genomics Medicine Ireland from ARCH Venture Partners, GV, Ireland Strategic Investment Fund, and Polaris Partners. The company has completed 2 deals to date, with its most recent significant funding round being a Series A round, where it raised USD 40.00 mn led by GV, with participation from ARCH Venture Partners, Ireland Strategic Investment Fund, and Polaris Partners.Genomics Medicine Ireland (GMI) delivers genomic solutions designed to enhance healthcare through a better understanding of genetic factors influencing diseases. Their primary offerings include advanced genomic sequencing and bioinformatics solutions that enable clinicians and researchers to analyze genetic data, providing important insights for personalized treatment strategies. GMI serves healthcare institutions, research organizations, and biopharmaceutical companies across Europe and North America, facilitating precision medicine initiatives tailored to specific populations and conditions.In 2022, Genomics Medicine Ireland reported a revenue of USD 7,465,884. The company operates on a B2B model, generating revenue through contractual agreements with healthcare providers and research institutions for genomic testing and data analysis services. This model supports flagship offerings such as whole-genome sequencing and tailored genomic profiling, with pricing structures negotiated to meet client needs. GMI's commitment to innovation and continuous product development strengthens its position in the genomics market.Genomics Medicine Ireland plans to expand its product offerings by launching new genomic solutions in the coming years. Additionally, the company aims to penetrate new markets in North America and Europe by 2025, enhancing its presence in these regions. The funding raised in the Series A round is expected to support these initiatives, particularly in product development and market expansion efforts.

## Funding rounds

- Series A, Oct 26, 2016, $40M — ARCH Venture Partners, Polaris Partners, Ireland Strategic Investment Fund, GV

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- Ireland Strategic Investment Fund — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A